These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
549 related articles for article (PubMed ID: 26253079)
41. The role of B. pertussis vaccine antigen gene variants in pertussis resurgence and possible consequences for vaccine development. Preston A Hum Vaccin Immunother; 2016 May; 12(5):1274-6. PubMed ID: 26889694 [TBL] [Abstract][Full Text] [Related]
43. Development of vaccines against pertussis caused by Bordetella holmesii using a mouse intranasal challenge model. Saito M; Odanaka K; Otsuka N; Kamachi K; Watanabe M Microbiol Immunol; 2016 Sep; 60(9):599-608. PubMed ID: 27515393 [TBL] [Abstract][Full Text] [Related]
44. A nested case-control study measuring pertussis vaccine effectiveness and duration of protection in Manitoba, Canada, 1992-2015: A Canadian Immunization Research Network Study. Wilkinson K; Righolt CH; Kwong JC; Schwartz KL; Russell ML; Crowcroft NS; Mahmud SM Vaccine; 2019 Nov; 37(48):7132-7137. PubMed ID: 31564453 [TBL] [Abstract][Full Text] [Related]
45. Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model. Komatsu E; Yamaguchi F; Eguchi M; Watanabe M Vaccine; 2010 Jun; 28(27):4362-8. PubMed ID: 20438876 [TBL] [Abstract][Full Text] [Related]
52. Pathogenesis and histopathology of pertussis: implications for immunization. Cherry JD; Paddock CD Expert Rev Vaccines; 2014 Sep; 13(9):1115-23. PubMed ID: 24992986 [TBL] [Abstract][Full Text] [Related]
53. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A; Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665 [TBL] [Abstract][Full Text] [Related]
54. Licensed pertussis vaccines in the United States. History and current state. Klein NP Hum Vaccin Immunother; 2014; 10(9):2684-90. PubMed ID: 25483496 [TBL] [Abstract][Full Text] [Related]
55. Resurgence of pertussis calls for re-evaluation of pertussis animal models. van der Ark AA; Hozbor DF; Boog CJ; Metz B; van den Dobbelsteen GP; van Els CA Expert Rev Vaccines; 2012 Sep; 11(9):1121-37. PubMed ID: 23151168 [TBL] [Abstract][Full Text] [Related]
56. [Efficacy of acellular pertussis vaccines]. Wirsing von König CH; Finger H Immun Infekt; 1995 Aug; 23(4):125-9. PubMed ID: 7558115 [TBL] [Abstract][Full Text] [Related]
57. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3. Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898 [TBL] [Abstract][Full Text] [Related]
58. Is there a need for a new generation of vaccines against pertussis? Storsaeter J; Wolter J Expert Opin Emerg Drugs; 2006 May; 11(2):195-205. PubMed ID: 16634696 [TBL] [Abstract][Full Text] [Related]
59. Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination. Smits K; Pottier G; Smet J; Dirix V; Vermeulen F; De Schutter I; Carollo M; Locht C; Ausiello CM; Mascart F Vaccine; 2013 Dec; 32(1):111-8. PubMed ID: 24176499 [TBL] [Abstract][Full Text] [Related]
60. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Feunou PF; Kammoun H; Debrie AS; Mielcarek N; Locht C Vaccine; 2010 Oct; 28(43):7047-53. PubMed ID: 20708998 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]